INLB (Item 9 Labs) EBIT: $-21.66 Mil (TTM As of Jun. 2023)

What is Item 9 Labs EBIT?

Item 9 Labs INLB -99.00% 12 EBIT is $-21.66 Mil as of Jun. 2023. GuruFocus rates INLB with a GF Score™ of 12/100.

Item 9 Labs's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $-2.96 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-21.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Item 9 Labs's annualized ROC % for the quarter that ended in Jun. 2023 was -7.72%. Item 9 Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -46.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Item 9 Labs (OTCPK:INLB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Item 9 Labs's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-11.188 * ( 1 - 0.02% )	/	( (141.108	+	148.493)	/ 2 )
=	-11.1857624	/	144.8005
=	-7.72 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	114.127	-	16.474	-	( 0.101	-	max(0, 47.136	-	3.681	+	0.101	))
=	141.108

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	112.015	-	18.988	-	( 0.183	-	max(0, 58.813	-	3.347	+	0.183	))
=	148.493

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Item 9 Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.856	/	( ( (25.767 + max(-18.569, 0))	+	(24.968 + max(-21.499, 0)) )	/	2 )
=	-11.856	/	( ( 25.767	+	24.968 )	/	2 )
=	-11.856	/	25.3675
=	-46.74 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.596	+	2.641	+	0.343)	-	(16.474	+	0.175	+	5.5)
=	-18.569

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.968	+	1.899	+	0.297)	-	(18.988	+	0.175	+	5.5)
=	-21.499

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Item 9 Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-21.659	/	0.000
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Item 9 Labs EBIT Related Terms

Item 9 Labs EBIT Historical Data

* Premium members only.

The historical data trend for Item 9 Labs's EBIT can be seen below:

Item 9 Labs EBIT Chart

Item 9 Labs Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

EBIT

Get a 7-Day Free Trial

-0.66

-9.61

-5.43

-5.61

-24.75

Item 9 Labs Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial															-3.85	-16.00	-1.40	-1.30	-2.96

INLB vs NEPT, CENBF, SGBI: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Item 9 Labs EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's EV-to-EBIT falls into.

Save Embed

12GF Score

Item 9 Labs Corp INLB

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Item 9 Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.66 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-21.66 Mil mean?

Item 9 Labs (INLB) has a EBIT of $-21.66 Mil as of Jun. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Item 9 Labs.

Is Item 9 Labs' EBIT too high?

Item 9 Labs' current EBIT is $-21.66 Mil. Overall, Item 9 Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Item 9 Labs' EBIT compare to NEPT and CENBF?

Item 9 Labs' EBIT of $-21.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Item 9 Labs. Item 9 Labs's current EBIT is $-21.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Item 9 Labs stock overvalued right now?

Item 9 Labs (INLB) has a current EBIT of $-21.66 Mil. The current EBIT is $-21.66 Mil. Item 9 Labs' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Item 9 Labs (INLB), the current EBIT is $-21.66 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Item 9 Labs Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NEPT CENBF SGBI GCAN SKYI SNOA CANB KAYS PHBI MNKTQ ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692

Address 2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016

Website https://www.item9labscorp.com

Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.

12GF Score

Get the complete analysis for INLB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View INLB Analysis

See EBIT data for all stocks →